RelatedMajor crimes down in Trelawny Major crimes down in Trelawny National SecurityDecember 11, 2010 RelatedMajor crimes down in Trelawny FacebookTwitterWhatsAppEmail The Police are reporting a drop in all major crimes in the parish of Trelawny from January to December 4, when compared with the similar period for 2009.In a report tabled at the monthly meeting of the Trelawny Parish Council by Detective Sergeant Rainford Whyte, on December 9, the crime statistics are showing approximately 226 offences committed up to December 4, in comparison to 315 committed in the corresponding period for 2009.He credited the proactiveness of the police, the placement of additional officers on the streets; and co-operation from the public as some of the reasons for the inroads made in curtailing criminal activity in the parish.According to Mr. Whyte, 23 murders were committed in the parish up to December 4, in comparison to 32 for the corresponding period in 2009; there were 18 incidents of shooting, as against 22 in 2009; 10 rapes, as against 30 in 2009; 24 robberies, as against 48 in 2009; 23 carnal abuse cases, as against 28 in 2009; 121 break-ins, as against 138 in 2009, and 7 larceny cases, as against 17 in 2009.Mayor of Falmouth and Chairman of the Trelawny Parish Council, Colin Gager, expressed satisfaction with the report, adding that a low crime rate is what the residents of Trelawny expected.“We are always free from crime in Trelawny, but somewhere or the other, the dragon raised its head, but we can say that the police, because of their active work, have gotten crime under control, and we think that this will work beautifully for the projects that are coming on stream and we will be able to sell Trelawny as a crime free parish,” he said.All the Councillors at the meeting commended the police for the good work they have been doing throughout the parish. RelatedMajor crimes down in Trelawny Advertisements
AddThis Sharing ButtonsShare to LinkedInLinkedInLinkedInShare to TwitterTwitterTwitterShare to FacebookFacebookFacebookShare to MoreAddThisMore 15 JUL 2020 The General Court of the European Union annulled a 2016 European Commission (EC) decision to charge Apple €13 billion in back taxes, after ruling the EC was incorrect in concluding the company received illegal benefits in the Republic of Ireland.In a statement, the court noted the EC “did not succeed in showing to the requisite legal standard” that Apple subsidiaries incorporated in Ireland gained “a selective economic advantage and, by extension state aid”.Apple told Mobile World Live the case “was not about how much tax we pay, but where we are required to pay it”.The company highlighted it had “paid more than $100 billion” in corporate income tax and “tens of billions” in other taxes globally in the last decade, and said it spent more than €13 billion with 4,500 European suppliers in 2019, in turn supporting 1.8 million jobs.Ireland’s Department of Finance stated the country had “always been clear that there was no special treatment provided” to Apple.EC VP and Competition Commissioner Margrethe Vestager said it “will carefully study the judgment and reflect on possible next steps”.Apple began appeal proceedings in September 2019, when it labelled the EC’s ruling “fundamentally flawed”. Subscribe to our daily newsletter Back Apple Previous ArticleGoogle faces another data tracking lawsuitNext ArticleGoogle pumps billions into Jio Platforms Manny Pham Tags Google taps retail with NYC store Home Apple wins tax battle against EC UK consumers seek £1.5B from Apple Apps Author Related Manny joined Mobile World Live in September 2019 as a reporter based in London. He has previous experience in telecoms having worked for B2B publication Mobile News for three years where he climbed up to the position of Features Editor…. Read more KT makes LG Electronics trade-in move
BARDA has contracted for a total of 20 million doses of Imvamune, at a cost of $505 million. The government previously bought enough doses of the conventional vaccine to immunize the entire population. BARDA previously bought a total of 28.75 million doses of the anthrax vaccine BioThrax from Emergent BioSolutions, at a cost of $691 million. Project BioShield, established in 2004 and strengthened in 2006, provides authority and funds to support the development of countermeasures against chemical, biological, radiological, and nuclear threat agents. By the end of 2011, BARDA had acquired 57,102 doses of the monoclonal antibody Raxibacumab, used as an antitoxin to treat anthrax (Bacillus anthracis infection), from Human Genome Sciences. That includes 20,000 doses delivered under a fulfilled 2005 contract and 37,102 of 45,000 doses ordered under a 2009 contract option. For comparison, the total supply of Raxibacumab at the end of 2010 was 36,102 doses, according to earlier reports. “Project BioShield Annual Report to Congress” for 2011 Jul 28, 2011, CIDRAP News story covering renewal of preparedness law and 2010 annual report For botulism, BARDA has acquired 107,560 doses of Botulinum Antitoxin Therapeutic, made by Cangene, out of the 200,000 doses originally ordered. The supply at the end of 2010 was about 97,000 doses. BARDA’s medical countermeasures page The BioShield program is administered by the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). The new report is for calendar year 2011. For smallpox, by the end of 2011 BARDA had acquired 5.9 million doses of the Imvamune vaccine, made by Bavarian Nordic, up from 2.02 million doses a year earlier. The product is an attenuated vaccine intended for immunocompromised persons, who are at risk for complications from the conventional vaccinia virus vaccine. The agency also has ordered 1.7 million treatment courses of the experimental smallpox drug ST-246, made by SIGA Technologies, under a $433 million contract. None of that amount had been delivered by the end of last year, the report says. It says the contract “works toward the USG [US government] goal of developing two smallpox antivirals.” The report states, among other things, that the government has decided it doesn’t need the full 200,000 doses of an antitoxin for Clostridium botulinum (the botulism agent) that were ordered in 2006, instead settling for about 107,000 doses. The original contract for the product, which is derived from horse serum, was for $415 million. The report says $61 million was added to the contract to “maintain the horse herd, stockpile plasma, and continue stability testing of plasma and product in the SNS. This contract modification will ensure preparedness out to 2026.” “Reevaluation of the requirement led to a decrease in the number of doses necessary in the SNS [Strategic National Stockpile],” the report says. “Thus HHS/BARDA has met the requirement.” Sep 17, 2012 (CIDRAP News) – The recently released annual report for the federal Project BioShield program gives a snapshot of the US arsenal for blunting bioterrorist attacks, showing growth in the supplies of certain countermeasures for anthrax, botulism, and smallpox. In addition, in 2011 BARDA completed the acquisition of 10,000 doses of Anthrax Immune Globulin (AIG) from Cangene, also used to treat anthrax. The supply at the end of 2010 was listed as 7,327 doses. Total spending on Raxibacumab and AIG comes to $478 million, the report shows. See also: Oct 6, 2011, CIDRAP News story on BARDA’s 5-year plan
USA: Private sector inter-city rail project promoter Virgin Trains USA announced an initial public offering of 28·3 million shares of common stock on January 30. The expected price is between $17 and $19 per share.The shares are to be listed on the Nasdaq Global Select Market. Prior to the start of trading, Virgin Trains USA LLC would be converted to a Delaware corporation named Virgin Trains USA Inc. Virgin Trains USA was launched in November, when Virgin Group announced an agreement to make a minority investment in inter-city rail business Brightline, which is transitioning to the Virgin Trains USA brand.After the offering and concurrent private placements, private equity funds managed by an affiliate of Fortress Investment Group would own approximately 81·6% of the common stock, or 79·5% if the underwriters’ over-allotment option is fully exercised. A Virgin Group affiliate has agreed to purchase less than 2% of the shares outstanding following the offering.Barclays, JP Morgan and Morgan Stanley are acting as lead book-running managers. Additional book-running managers are BofA Merrill Lynch and Allen & Company LLC, and co-managers are JMP Securities, Raymond James and Stephens Inc.‘Too long to drive, too short to fly’The Brightline service currently operates between Miami, Fort Lauderdale and West Palm Beach in Florida, with plans to expand to Orlando and Tampa.Virgin Rail USA has also agreed to acquire the XpressWest project to develop a rail corridor connecting Las Vegas with southern California, and hopes to begin construction this year for completion by Q4 2022 or Q1 2023. The development costs would be funded with the net proceeds from the offering and/or other debt or equity financings.Virgin Trains USA said it intends the Florida and Las Vegas services to generate ‘meaningful’ profits and to be a scalable model for expansion in other congested ‘too long to drive, too short to fly’ inter-city corridors between highly-populated cities 300 to 500 km apart.